JP2011516400A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516400A5
JP2011516400A5 JP2010521046A JP2010521046A JP2011516400A5 JP 2011516400 A5 JP2011516400 A5 JP 2011516400A5 JP 2010521046 A JP2010521046 A JP 2010521046A JP 2010521046 A JP2010521046 A JP 2010521046A JP 2011516400 A5 JP2011516400 A5 JP 2011516400A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutical composition
inflammatory
eye
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521046A
Other languages
English (en)
Japanese (ja)
Other versions
JP5894364B2 (ja
JP2011516400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009776 external-priority patent/WO2009025763A2/en
Publication of JP2011516400A publication Critical patent/JP2011516400A/ja
Publication of JP2011516400A5 publication Critical patent/JP2011516400A5/ja
Application granted granted Critical
Publication of JP5894364B2 publication Critical patent/JP5894364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521046A 2007-08-16 2008-08-15 眼および付属器組織の炎症を処置するための治療組成物 Active JP5894364B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96513507P 2007-08-16 2007-08-16
US60/965,135 2007-08-16
US13068708P 2008-06-02 2008-06-02
US61/130,687 2008-06-02
PCT/US2008/009776 WO2009025763A2 (en) 2007-08-16 2008-08-15 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015227544A Division JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Publications (3)

Publication Number Publication Date
JP2011516400A JP2011516400A (ja) 2011-05-26
JP2011516400A5 true JP2011516400A5 (cg-RX-API-DMAC7.html) 2016-01-14
JP5894364B2 JP5894364B2 (ja) 2016-03-30

Family

ID=40378866

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521046A Active JP5894364B2 (ja) 2007-08-16 2008-08-15 眼および付属器組織の炎症を処置するための治療組成物
JP2015227544A Pending JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015227544A Pending JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Country Status (5)

Country Link
US (2) US10105441B2 (cg-RX-API-DMAC7.html)
EP (1) EP2187900B1 (cg-RX-API-DMAC7.html)
JP (2) JP5894364B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008289552B2 (cg-RX-API-DMAC7.html)
WO (1) WO2009025763A2 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
EP2385839B1 (en) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
WO2011050164A1 (en) 2009-10-21 2011-04-28 Avedro, Inc. Eye therapy
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2011116306A2 (en) 2010-03-19 2011-09-22 Avedro, Inc. Systems and methods for applying and monitoring eye therapy
US9095591B2 (en) * 2010-06-28 2015-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pharmaceutical composition for use in the treatment of glaucoma
US20120004298A1 (en) * 2010-06-30 2012-01-05 Hassan Chaouk Ophthalmic devices containing chemokine antagonists
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
WO2012148547A1 (en) * 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
WO2012118863A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Therapies that target autoimmunity for treating glaucoma and optic neuropathy
EP2686431B1 (en) 2011-03-14 2016-08-03 Phlogo ApS Antagonists of the interleukin- 1 receptor
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
WO2012162529A1 (en) 2011-05-24 2012-11-29 Avedro, Inc. Systems and methods for reshaping an eye feature
WO2012167260A2 (en) 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9812730B2 (en) 2011-08-02 2017-11-07 Johnson & Johnson Vision Care, Inc. Biocompatible wire battery
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
EP2872081B2 (en) 2012-07-16 2025-07-16 Avedro, Inc. Systems for corneal cross-linking with pulsed light
WO2014093870A2 (en) * 2012-12-13 2014-06-19 The Schepens Eye Research Institute, Inc. Use of c-c chemokine receptor type 7 (ccr7) inhibitors
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
TWI623313B (zh) * 2013-03-13 2018-05-11 Santen Pharmaceutical Co Ltd 瞼板腺功能障礙之治療劑
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
EP2991621B1 (en) * 2013-05-02 2020-12-09 Retina Foundation of the Southwest Two-layer ocular implant
US20140343480A1 (en) * 2013-05-19 2014-11-20 Avedro, Inc. Systems, methods, and compositions for cross-linking
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
WO2014205145A1 (en) 2013-06-18 2014-12-24 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
EP3212140B1 (en) 2014-10-27 2021-12-01 Avedro, Inc. Systems for cross-linking treatments of an eye
US10114205B2 (en) 2014-11-13 2018-10-30 Avedro, Inc. Multipass virtually imaged phased array etalon
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10478394B2 (en) * 2015-03-11 2019-11-19 Wayne State University Compositions and methods to promote wound healing
EP3827792A1 (en) 2015-04-24 2021-06-02 Avedro, Inc. Systems and methods for photoactivating a photosensitizer applied to an eye
RU2728795C2 (ru) * 2015-04-28 2020-07-31 Свидиш Орфан Биовитрум Аб (Пабл) Композиции, содержащие анакинру
EP4483884A3 (en) 2015-05-22 2025-03-05 Avedro Inc. Systems for monitoring cross-linking activity for corneal treatments
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
CN105833234A (zh) * 2016-05-20 2016-08-10 刘传彬 一种纯天然加热外敷治疗筋骨伤痛的中药组合物
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
CN111936853A (zh) * 2018-03-13 2020-11-13 目立康株式会社 确定系统、计算装置、确定方法及程序
US12303527B2 (en) 2018-04-18 2025-05-20 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CN108707195B (zh) * 2018-05-31 2019-03-15 苏州大学 翘嘴鳜IFN-α3基因、重组蛋白、制备方法及应用
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
EP3852734A1 (en) * 2018-09-22 2021-07-28 Novaliq GmbH Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
CN110437043A (zh) * 2019-08-24 2019-11-12 黄泳华 由白藜芦醇与前列腺素类似物剂构成的共晶及其在制备抗肿瘤药物中的用途
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
CN116144668A (zh) * 2023-02-13 2023-05-23 杭州吉倍思生物制药有限公司 人il-1r1基因、蛋白、同源二聚体蛋白质与用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
HK1006856A1 (en) 1989-11-29 1999-03-19 Amgen Inc. Production of recombinant human interleukin-1 inhibitor
EP0611302B1 (en) 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5895812A (en) 1995-05-01 1999-04-20 The University Of Virginia Alumni Patent Foundation Diagnostic for Sjogren's syndrome
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6416753B1 (en) 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
DK1676579T3 (da) 1998-05-08 2009-03-16 Univ Miami Anvendelse af sub-antimikrobielle tetracykliner til behandling af okulær rosacea
US6432934B1 (en) 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20060262813A1 (en) 1998-12-18 2006-11-23 Digital Networks North America, Inc. Multi-channel video pump
US6471961B1 (en) 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP3363832B2 (ja) 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
JP2002154985A (ja) 2000-01-31 2002-05-28 Santen Pharmaceut Co Ltd 眼疾患治療剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
WO2001057082A2 (en) 2000-02-03 2001-08-09 Regeneration Technologies, Inc. Extraction of growth factors from tissue
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US6890654B2 (en) 2002-04-18 2005-05-10 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
US7029712B1 (en) 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050033694A1 (en) 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
US20050023872A1 (en) 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko) 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
PL1729810T3 (pl) 2004-04-02 2019-02-28 Swedish Orphan Biovitrum Ab (Publ) Sposoby agregacji IL-1ra
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2006091546A2 (en) 2005-02-22 2006-08-31 The Johns Hopkins School Of Medicine Use of amniotic fluid (af) in treating ocular disease and injury
CN102293774A (zh) * 2005-03-31 2011-12-28 旭硝子株式会社 前列腺素F2α衍生物的应用
EP1870099A4 (en) * 2005-04-13 2008-07-16 Ube Industries PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US20070248597A1 (en) 2005-10-21 2007-10-25 Henley Charles M Iii Methods of decreasing vascular calcification using IL-1 inhibitors
WO2007056812A1 (en) * 2005-11-16 2007-05-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 il-1 항체의 용도
CN101489569A (zh) 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20080312194A1 (en) 2007-02-28 2008-12-18 Ousler Iii George W Methods and compositions for normalizing meibomian gland secretions
US7758190B2 (en) 2007-06-20 2010-07-20 Tearscience, Inc. Tear film measurement
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders

Similar Documents

Publication Publication Date Title
JP5894364B2 (ja) 眼および付属器組織の炎症を処置するための治療組成物
Colligris et al. Recent developments on dry eye disease treatment compounds
US10940179B2 (en) Therapeutic compositions for the treatment of dry eye disease
EP2242504B1 (en) Therapeutic compositions for treatment of ocular inflammatory disorders
AU2010203425B2 (en) Therapeutic compositions for treatment of corneal disorders
Skaat et al. Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
CA2640986C (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
US11306140B2 (en) Therapeutics for ocular immunoinflammatory diseases
CN114206849B (zh) 用于治疗非感染性眼部免疫炎性病症的治疗方法
WO2014093870A2 (en) Use of c-c chemokine receptor type 7 (ccr7) inhibitors
Shetty et al. Biological cleansing: Toward improving ocular surface surgical outcomes
Mautino et al. Side effects of drugs used in ocular treatment